ERBB2 and breast carcinoma: Our study thereby validates the Recurrence Score test as a predictor of clinical response to six months of neoadjuvant letrozole in postmenopausal patients with ER+, HER2-negative, clinically node-negative, non-metastatic primary early breast cancer.